V
83.98
-0.83 (-0.98%)
| Previous Close | 84.81 |
| Open | 84.50 |
| Volume | 1,316,240 |
| Avg. Volume (3M) | 1,405,753 |
| Market Cap | 7,136,527,872 |
| Price / Sales | 64.24 |
| Price / Book | 34.64 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -138.31% |
| Operating Margin (TTM) | -13.53% |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 107.63% |
| Current Ratio (MRQ) | 8.86 |
| Operating Cash Flow (TTM) | -120.15 M |
| Levered Free Cash Flow (TTM) | -69.15 M |
| Return on Assets (TTM) | -20.64% |
| Return on Equity (TTM) | -72.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Verona Pharma plc | Bullish | Bullish |
AIStockmoo Score
1.5
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.88% |
| % Held by Institutions | 90.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 31 Mar 2025 | 2,323,115 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 160.00 (Piper Sandler, 90.52%) | Buy |
| Median | 113.00 (34.56%) | |
| Low | 90.00 (HC Wainwright & Co., 7.17%) | Buy |
| Average | 119.00 (41.70%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 74.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 23 Jun 2025 | 160.00 (90.52%) | Buy | 0.000 |
| Wells Fargo | 20 Jun 2025 | 138.00 (64.32%) | Buy | 92.20 |
| 30 Apr 2025 | 107.00 (27.41%) | Buy | 72.07 | |
| Roth Capital | 18 Jun 2025 | 116.00 (38.13%) | Buy | 92.20 |
| Cantor Fitzgerald | 11 Jun 2025 | 100.00 (19.08%) | Buy | 90.05 |
| Jefferies | 11 Jun 2025 | 110.00 (30.98%) | Buy | 90.05 |
| HC Wainwright & Co. | 02 Jun 2025 | 90.00 (7.17%) | Buy | 84.10 |
| 30 Apr 2025 | 85.00 (1.21%) | Buy | 72.07 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HAHN MARK W | - | 90.05 | -400,000 | -36,020,000 |
| ZACCARDELLI DAVID | - | 90.05 | -400,000 | -36,020,000 |
| Aggregate Net Quantity | -800,000 | |||
| Aggregate Net Value ($) | -72,040,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 90.05 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ZACCARDELLI DAVID | Officer | 11 Jun 2025 | Automatic sell (-) | 400,000 | 90.05 | 36,020,000 |
| HAHN MARK W | Officer | 11 Jun 2025 | Automatic sell (-) | 400,000 | 90.05 | 36,020,000 |
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors |
| 23 Jun 2025 | Announcement | Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors |
| 21 May 2025 | Announcement | Verona Pharma Announces June 2025 Investor Conference Participation |
| 06 May 2025 | Announcement | Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 |
| 29 Apr 2025 | Announcement | Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 16 Apr 2025 | Announcement | Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre |
| 15 Apr 2025 | Announcement | Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update |
| 28 Mar 2025 | Announcement | Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |